Does Rallies show 13F holders for CUE?

Yes. Rallies tracks hedge fund and 13F ownership data for CUE, including fund names, share counts, latest tracked quarter, and position changes when available.

Is CUE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CUE. It does not provide personalized investment advice.

CUE (Cue Biopharma, Inc.) Stock Analysis - Hedge Fund Holdings

Cue Biopharma, Inc. (CUE) is a publicly traded Healthcare sector company. As of May 21, 2026, CUE trades at $20.03 with a market cap of $86.50M and a P/E ratio of -16.45. CUE moved -1.53% today. Year to date, CUE is +77.99%; over the trailing twelve months it is +1.70%. Its 52-week range spans $4.97 to $59.67. Rallies surfaces CUE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns CUE stock?

Hedge funds tracked by Rallies that own CUE include Renaissance Technologies and Citadel Advisors. The latest tracked quarter is Mar 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Cue Biopharma, Inc..

CUE Key Metrics

Key financial metrics for CUE
Metric	Value
Price	$20.03
Market Cap	$86.50M
P/E Ratio	-16.45
EPS	$-1.21
Dividend Yield	0.00%
52-Week High	$59.67
52-Week Low	$4.97
Volume	386
Avg Volume	0
Revenue (TTM)	$32.73M
Net Income	$-19.52M
Gross Margin	0.00%

Top Hedge Funds Holding CUE

Renaissance Technologies holds 274.03K shares of CUE, changed +214.26% as of Mar 31, 2024.
Citadel Advisors holds 1.20K shares of CUE, changed -53.85% as of Dec 31, 2024.

Latest CUE News

Cue Biopharma Raises $30M, Earns $7.5M Milestone, Licenses CUE-221 and Preps INDs — May 14, 2026
Cue Biopharma Names Shao-Lee Lin CEO, Plans Phase 1 CUE-401 and Phase 2 Launch — Apr 30, 2026
1-for-30 Reverse Split to Cut Shares to 3.3M and Secure Nasdaq Listing — Apr 22, 2026
Cue Biopharma Earns $7.5M Preclinical Milestone from Boehringer Ingelheim — Apr 8, 2026
Cue Biopharma Appoints Lucinda Warren Interim CEO to Drive CUE-401 Clinic Entry — Mar 27, 2026

Recent CUE Insider Trades

Sarraf Pasha bought 4.23K (~$1.31K) on Dec 30, 2025.
Sarraf Pasha bought 77.15K (~$23.17K) on Dec 30, 2025.
Sarraf Pasha bought 86.95K (~$27.60K) on Dec 30, 2025.

CUE Analyst Consensus

CUE analyst coverage data. Average price target: $0.00.

Common questions about CUE

Who owns CUE stock?: Hedge funds tracked by Rallies that own CUE include Renaissance Technologies and Citadel Advisors. The latest tracked quarter is Mar 31, 2024. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Cue Biopharma, Inc..
Does Rallies show 13F holders for CUE?: Yes. Rallies tracks hedge fund and 13F ownership data for CUE, including fund names, share counts, latest tracked quarter, and position changes when available.
Is CUE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CUE. It does not provide personalized investment advice.